BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
43.99
+1.16 (2.71%)
At close: Jul 3, 2025, 1:00 PM
44.00
+0.01 (0.02%)
After-hours: Jul 3, 2025, 3:59 PM EDT
BridgeBio Pharma Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$174,541
Profits / Employee
-$915,025
Market Cap
8.35B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BBIO News
- 5 days ago - BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty - GlobeNewsWire
- 9 days ago - BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET - GlobeNewsWire
- 4 weeks ago - BridgeBio: New Data Bolsters The Bull Case - Seeking Alpha
- 4 weeks ago - BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewsWire
- 6 weeks ago - Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - GlobeNewsWire
- 6 weeks ago - Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - GlobeNewsWire
- 7 weeks ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - GlobeNewsWire